Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 2
1998 2
1999 4
2000 18
2001 10
2002 8
2003 26
2004 21
2005 25
2006 26
2007 37
2008 51
2009 59
2010 66
2011 74
2012 105
2013 115
2014 142
2015 166
2016 190
2017 217
2018 270
2019 280
2020 341
2021 343
2022 260
2023 245
2024 138

Text availability

Article attribute

Article type

Publication date

Search Results

2,783 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "BLOOD GROUP--LUTHERAN INHIBITOR"
Page 1
Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.
Sachar H, Vaidya K, Laine L. Sachar H, et al. JAMA Intern Med. 2014 Nov;174(11):1755-62. doi: 10.1001/jamainternmed.2014.4056. JAMA Intern Med. 2014. PMID: 25201154 Free PMC article. Review.
IMPORTANCE: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor (PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding ulcers. ...Risk ratios for rebleeding within 30 days and 3 days, mortality, …
IMPORTANCE: Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor (PPI) followed by continuous PPI infusi …
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials.
Khairani CD, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller SC, Cortes-Hernandez J, Connors JM, Kanthi Y, Krumholz HM, Middeldorp S, Falanga A, Cushman M, Goldhaber SZ, Garcia DA, Bikdeli B. Khairani CD, et al. J Am Coll Cardiol. 2023 Jan 3;81(1):16-30. doi: 10.1016/j.jacc.2022.10.008. Epub 2022 Oct 31. J Am Coll Cardiol. 2023. PMID: 36328154 Free PMC article.
OBJECTIVES: The authors performed a systematic review and meta-analysis of randomized controlled trials that compared DOACs with vitamin K antagonists (VKAs). METHODS: We searched PubMed, EMBASE, and Cochrane Central Register of Controlled Trials through April 9, 2022. ...
OBJECTIVES: The authors performed a systematic review and meta-analysis of randomized controlled trials that compared DOACs with vitamin K …
Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.
Kanno T, Yuan Y, Tse F, Howden CW, Moayyedi P, Leontiadis GI. Kanno T, et al. Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD005415. doi: 10.1002/14651858.CD005415.pub4. Cochrane Database Syst Rev. 2022. PMID: 34995368 Free PMC article. Review.
However, there is conflicting evidence regarding the clinical efficacy of proton pump inhibitors initiated before endoscopy in people with upper gastrointestinal bleeding. ...Outcomes assessed at 30 days were: mortality (our primary outcome), rebleeding, surgery, high-risk …
However, there is conflicting evidence regarding the clinical efficacy of proton pump inhibitors initiated before endoscopy in people …
Management of acute upper gastrointestinal bleeding.
Stanley AJ, Laine L. Stanley AJ, et al. BMJ. 2019 Mar 25;364:l536. doi: 10.1136/bmj.l536. BMJ. 2019. PMID: 30910853
For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin threshold of 70-80 g/L are recommended. After resuscitation is initiated, proton pump inhibitors (PPIs) and the prokinetic agent erythromycin may be administered …
For all other patients, intravenous fluids as needed for resuscitation and red cell transfusion at a hemoglobin threshold of 70-80 g/L are r …
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update.
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Key NS, et al. J Clin Oncol. 2023 Jun 1;41(16):3063-3071. doi: 10.1200/JCO.23.00294. Epub 2023 Apr 19. J Clin Oncol. 2023. PMID: 37075273
RESULTS: Five RCTs provided information that contributed to changes to the 2019 recommendations. Two RCTs addressed direct factor Xa inhibitors (either rivaroxaban or apixaban) for extended thromboprophylaxis after surgery. ...
RESULTS: Five RCTs provided information that contributed to changes to the 2019 recommendations. Two RCTs addressed direct factor Xa inhi …
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Proietti M, et al. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22. Stroke. 2018. PMID: 29167388 Free article. Review.
The risk of major bleeding was significantly lower for apixaban compared with warfarin, dabigatran, and rivaroxaban (relative risk reduction, 38%, 35%, and 46%, respectively). Similarly, the risk for intracranial hemorrhage was significantly lower for apixaban than warfari …
The risk of major bleeding was significantly lower for apixaban compared with warfarin, dabigatran, and rivaroxaban (relative risk reduction …
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.
Wang X, Ma Y, Hui X, Li M, Li J, Tian J, Wang Q, Yan P, Li J, Xie P, Yang K, Yao L. Wang X, et al. Cochrane Database Syst Rev. 2023 Apr 14;4(4):CD010956. doi: 10.1002/14651858.CD010956.pub3. Cochrane Database Syst Rev. 2023. PMID: 37058421 Free PMC article. Review.
Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTIs) and oral factor Xa inhibitors, which have characteris …
Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of direct oral anticoagul …
Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis.
Wang Y, Ye Z, Ge L, Siemieniuk RAC, Wang X, Wang Y, Hou L, Ma Z, Agoritsas T, Vandvik PO, Perner A, Møller MH, Guyatt GH, Liu L. Wang Y, et al. BMJ. 2020 Jan 6;368:l6744. doi: 10.1136/bmj.l6744. BMJ. 2020. PMID: 31907166 Free PMC article.
OBJECTIVE: To determine, in critically ill patients, the relative impact of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), sucralfate, or no gastrointestinal bleeding prophylaxis (or stress ulcer prophylaxis) on outcomes important to patien …
OBJECTIVE: To determine, in critically ill patients, the relative impact of proton pump inhibitors (PPIs), histamine-2 receptor an …
Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis.
Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini GG. Chiarito M, et al. Lancet. 2020 May 9;395(10235):1487-1495. doi: 10.1016/S0140-6736(20)30315-9. Lancet. 2020. PMID: 32386592
BACKGROUND: Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y(12) inhibitor versus aspirin for secondary prevention. METHODS: In this systematic review and meta-analysis, all randomised trials comparing …
BACKGROUND: Antiplatelet therapy is recommended among patients with established atherosclerosis. We compared monotherapy with a P2Y(12) i …
Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Pan KL, et al. J Am Heart Assoc. 2017 Jul 18;6(7):e005835. doi: 10.1161/JAHA.117.005835. J Am Heart Assoc. 2017. PMID: 28720644 Free PMC article. Review.
Pooling results from included trials showed that NOACs versus warfarin reduced stroke or systemic embolism (HR: 0.70; 95% CI, 0.60-0.82) and intracranial hemorrhage (HR: 0.47; 95% CI, 0.24-0.92) in AF patients with VHD. However, risk reduction of major bleeding and intracr …
Pooling results from included trials showed that NOACs versus warfarin reduced stroke or systemic embolism (HR: 0.70; 95% CI, 0.60-0.82) and …
2,783 results